Cannara Biotech Inc
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. I… Read more
Cannara Biotech Inc (LOVFF) - Net Assets
Latest net assets as of November 2025: $111.21 Million USD
Based on the latest financial reports, Cannara Biotech Inc (LOVFF) has net assets worth $111.21 Million USD as of November 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($173.84 Million) and total liabilities ($62.63 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $111.21 Million |
| % of Total Assets | 63.97% |
| Annual Growth Rate | 31.86% |
| 5-Year Change | 59.43% |
| 10-Year Change | N/A |
| Growth Volatility | 81.9 |
Cannara Biotech Inc - Net Assets Trend (2018–2025)
This chart illustrates how Cannara Biotech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cannara Biotech Inc (2018–2025)
The table below shows the annual net assets of Cannara Biotech Inc from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-08-31 | $102.22 Million | +16.22% |
| 2024-08-31 | $87.95 Million | +10.29% |
| 2023-08-31 | $79.74 Million | +19.49% |
| 2022-08-31 | $66.74 Million | +4.09% |
| 2021-08-31 | $64.12 Million | +67.12% |
| 2020-08-31 | $38.36 Million | -23.16% |
| 2019-08-31 | $49.93 Million | +238.67% |
| 2018-08-31 | $14.74 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cannara Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 229117700.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (August 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $178.28K | 0.17% |
| Other Components | $102.04 Million | 99.83% |
| Total Equity | $102.22 Million | 100.00% |
Cannara Biotech Inc Competitors by Market Cap
The table below lists competitors of Cannara Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Openbase Inc
KQ:049480
|
$35.36 Million |
|
Sunmow Holding Bhd
KLSE:03050
|
$35.36 Million |
|
MS Industrie AG
F:MSAG
|
$35.36 Million |
|
AIFORIA TECHNOLOGIES OYJ
F:L6J
|
$35.37 Million |
|
Sumeeko Industries Co Ltd
TWO:2066
|
$35.33 Million |
|
CompX International Inc
NYSE MKT:CIX
|
$35.32 Million |
|
The Beachbody Company, Inc.
NYSE:BODI
|
$35.31 Million |
|
Intchains Group Limited American Depositary Shares
NASDAQ:ICG
|
$35.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cannara Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 87,951,489 to 102,220,977, a change of 14,269,488 (16.2%).
- Net income of 13,076,193 contributed positively to equity growth.
- Other factors increased equity by 1,193,295.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $13.08 Million | +12.79% |
| Other Changes | $1.19 Million | +1.17% |
| Total Change | $- | 16.22% |
Book Value vs Market Value Analysis
This analysis compares Cannara Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.74x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 39.21x to 0.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-08-31 | $0.02 | $0.83 | x |
| 2019-08-31 | $0.07 | $0.83 | x |
| 2020-08-31 | $0.05 | $0.83 | x |
| 2021-08-31 | $0.07 | $0.83 | x |
| 2022-08-31 | $0.08 | $0.83 | x |
| 2023-08-31 | $0.88 | $0.83 | x |
| 2024-08-31 | $0.98 | $0.83 | x |
| 2025-08-31 | $1.12 | $0.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cannara Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.79%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.20%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 1.65x
- Recent ROE (12.79%) is above the historical average (-5.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -14.33% | -488.38% | 0.01x | 1.96x | $-3.59 Million |
| 2019 | -26.11% | -587.28% | 0.03x | 1.44x | $-17.03 Million |
| 2020 | -32.54% | -504.40% | 0.05x | 1.43x | $-16.32 Million |
| 2021 | -2.38% | -9.38% | 0.18x | 1.44x | $-7.94 Million |
| 2022 | 3.45% | 6.43% | 0.29x | 1.88x | $-4.37 Million |
| 2023 | 8.71% | 12.13% | 0.40x | 1.77x | $-1.03 Million |
| 2024 | 7.32% | 7.88% | 0.53x | 1.76x | $-2.36 Million |
| 2025 | 12.79% | 12.20% | 0.64x | 1.65x | $2.85 Million |
Industry Comparison
This section compares Cannara Biotech Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $580,491,146
- Average return on equity (ROE) among peers: -45.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cannara Biotech Inc (LOVFF) | $111.21 Million | -14.33% | 0.56x | $35.34 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $14.78 Million | -64.19% | 0.99x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-241.47K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -329.21% | 0.78x | $194.64 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $37.06 Million | 39.05% | 0.16x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $32.70 Million | -18.88% | 0.16x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.84 |
| Adcock Ingram Holdings Limited (AIHLF) | $4.54 Billion | 14.90% | 0.58x | $85.61 Million |